文献速递主动脉疾病

Meta分析提示他汀可降低腹主动脉瘤修复术后死亡率

Meta-analysis suggests statins reduce mortality after abdominal aortic aneurysm repair.
PubMed 文献 · J Vasc Surg · 2021-06-28

该系统综述与Meta分析检索Cochrane、Embase和MedLine,纳入1项随机试验事后分析和36项队列研究(共134290例未破裂腹主动脉瘤患者)。结果显示,他汀治疗与长期死亡率(OR 0.67,95%CI 0.59-0.75,P<.001)和短期死亡率(OR 0.51,95%CI 0.36-0.73,P<.001)显著降低相关,但围术期心血管并发症、内漏术后瘤囊缩小及瘤体生长速率无显著差异。

要点

  • 他汀治疗与腹主动脉瘤修复术后长期死亡率显著降低相关(OR 0.67)。
  • 他汀治疗与腹主动脉瘤修复术后短期死亡率显著降低相关(OR 0.51)。
  • 他汀对围术期心血管并发症、瘤囊缩小及瘤体生长速率无显著影响。

核心结论

  • 他汀使用与腹主动脉瘤修复术后长期和短期死亡率显著降低相关。
  • 基于此结果,他汀治疗值得在腹主动脉瘤临床管理中应用。

研究设计与样本

  • 系统综述与Meta分析,检索Cochrane library、Embase和MedLine。
  • 纳入1项随机试验事后分析和36项队列研究,共134290例患者。
  • 纳入研究平均Newcastle-Ottawa量表评分为7.76。
  • 采用随机效应模型合并结果。

主要发现

  • 他汀治疗组长期死亡率显著低于非使用者(OR 0.67,95%CI 0.59-0.75,P<.001,I2=71.7%)。
  • 他汀治疗组动脉瘤修复术后短期死亡率显著低于非使用者(OR 0.51,95%CI 0.36-0.73,P<.001,I2=81.4%)。
  • 围术期心血管并发症、血管内修复术后瘤囊缩小及监测下腹主动脉瘤生长速率在他汀使用者与非使用者间无显著差异。

关键数值与推荐

  • 短期死亡率定义为术后30天或住院期间全因死亡率。
  • 长期死亡率定义为随访结束时(≥1年)全因死亡率。
  • 纳入患者均诊断为未破裂腹主动脉瘤,其中59.9%接受他汀治疗。

临床怎么用

  • 对于未破裂腹主动脉瘤患者,可考虑使用他汀以降低修复术后短期和长期死亡风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The necessity and efficacy of statin treatment for abdominal aortic aneurysm (AAA) remains controversial. This systematic review and meta-analysis was conducted to investigate the effects of statin therapy on the outcomes of patients with AAA. METHODS: The Cochrane library, Embase, and MedLine were searched comprehensively to identify relevant cohort studies and randomized controlled trials. The primary outcomes included short- and long-term mortality after AAA repair, and secondary outcomes included the incidence of perioperative cardiovascular complications, sac shrinkage after endovascular aneurysm repair, and the growth rate of the aneurysms. Short-term mortality was defined as all-cause 30-day or in-hospital postoperative mortality. Long-term mortality was defined as the all-cause mortality at the end of follow-up period (≥1 year). A random effects model was used to combine the results of included studies. Forest plots were created to show the pooled results of each outcome. RESULTS: One post hoc analysis of a randomized trial and 36 cohort studies (n = 134,290 patients) were included in this systematic review. The average score of included studies by Newcastle-Ottawa Scale was 7.76. Patients taking or not taking statin therapy were all diagnosed with unruptured AAA, and 59.9% of these patients were given statin therapy. Compared with statin nonusers, patients in statin therapy had significantly lower long-term mortality (odds ratio, 0.67; 95% confidence interval, 0.59-0.75; P < .001; I2 = 71.7%), and short-term mortality after aneurysmal repair (odds ratio, 0.51; 95% confidence interval, 0.36-0.73; P < .001; I2 = 81.4%). No significant difference was found between patients taking or not taking statin treatment on perioperative cardiovascular complications or sac shrinkage after endovascular aneurysm repair or growth rate of AAA under surveillance. CONCLUSIONS: These findings suggest that statin use is associated with a significant decrease in long- and short-term mortality in patients after AAA repair. Based on these results, statin therapy is worth being used in clinical practice for the management of AAA.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Xiong X, Wu Z, Qin X, et al. Meta-analysis suggests statins reduce mortality after abdominal aortic aneurysm repair. J Vasc Surg. 2021. PMID: 34197945. doi:10.1016/j.jvs.2021.06.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。